

## References

### I-29

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Becker MA. Prevention of recurrent gout: Pharmacologic urate-lowering therapy and treatment of tophi. UpToDate Inc., Waltham, MA. Last reviewed January 2016.
3. American College of Rheumatology. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Accessed April 21, 2017.
4. Krystexxa® (pegloticase) for intravenous infusion [package insert]. Horizon Therapeutics USA, Inc. Lake Forest, IL.; Revised 01/2020.
5. Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. *Arthritis Res Ther.* 2017;19:191.
6. Cunha RN, Aguiar R, Farinha F. Impact of pegloticase on patient outcomes in refractory gout: Current perspectives. *Rheumatology: Research & Reviews.* 2018;10:141-149.
7. Schlesinger N, Edwards NL, Yeo AE, et. al. Development of a multivariable improvement measure for gout. *Arthritis Research & Therapy.* 2020;22(1):1-10.
8. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. Pegloticase.
9. Micromedex DrugDex Compendium®. 2020. Pegloticase (Krystexxa).